Potential predictive biomarker of response to VEGF treatment in metastatic kidney cancer

A recent study published on PLOS/ONE has identified three genetic mutations/alterations that are strongly predictive of progression-free survival in patients receiving first-line treatment with a vascular endothelial growth factor (VEGF) inhibitor for metastatic kidney cancer. The genes involved are TP53, wild type VHL and variants of FLT1C/C. Kidney cancer patients who did not have a mutation/alteration […]

read more

ESOU 2019: First-line treatment for metastatic renal cell carcinoma – where do we stand?

The following review of the literature for first-line treatment of metastatic renal cell carcinoma (RCC) was presented at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) conference in Prague, Czech Republic last week. The current paradigm for the first- and second-line treatment of RCC was presented based upon patient risk according to the International Metastatic Renal […]

read more

Potential biomarkers may predict response to TKIs in metastatic kidney cancer

A recent study published in Clinical Cancer Research and conducted in France has identified potential biological markers that are related to the formation of new blood vessels (angiogenesis) and regulated by the levels of oxygen reaching the tissues (hypoxia). These biomarkers have been found to be strong predictors of response, progression-free survival (PFS), and overall survival […]

read more

Management of bone metastases in renal cell carcinoma

The following video from Practise Update is an interview with Dr Dominick Bosse, Genitourinary Oncology Fellow from the Dana Farber Cancer Institute, Boston, USA. During this interview, Dr Bosse discusses the current state of treatment for patients with bone metastases from renal cell carcinoma (RCC), and the ongoing research in this area. View the video […]

read more

Nivolumab and cabozantinib accepted for use within NHS Scotland for advanced kidney cancer

The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending two new kidney cancer medicines for routine use by NHS Scotland. Nivolumab (Opdivo), an immunotherapy for advanced kidney cancer, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is for medicines used at the end of life […]

read more

Aflibercept shows promise in second-line treatment of advanced kidney cancer

A study reported in the online PracticeUpdate journal Renal Cell Carcinoma this week shows aflibercept, a vascular endothelial growth factor receptor (VEGFR) inhibitor, prolongs progression-free survival in people with previously treated advanced clear cell renal cell carcinoma (ccRCC). Patients with previously treated advanced or metastatic ccRCC were treated with one of two doses of aflibercept (1 […]

read more

Immunotherapy combined with VEGF inhibitors for kidney cancer

In this video interview, Dr Shilpa Gupta, assistant professor, Haematology, Oncology and Transplantation Division, University of Minnesota, USA, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer. Since kidney cancer is a VEGF-driven disease, it makes sense to combine VEGF inhibitors, such as sunitinib or axitinib, with immunotherapy drugs, such as nivolumab or […]

read more

Management of renal medullary carcinoma

Renal medullary carcinoma is a very rare subtype of renal cell carcinoma. This is a very devastating tumour, and it affects mostly patients of African descent, and patients with the sickle-cell trait. These patients in general have a survival of about one year from diagnosis, which is very devastating in this typically young patient population. […]

read more
Showing all 8 results
  TOP